United States · FDA National Drug Code directory
Trelegy Ellipta
A source-listed medicine record.
Factual source checks only. This page is not a clinically reviewed monograph. Historical or discontinued records may be included; listing does not confirm approval, current availability or pharmacy stock.
Medicine identity
- Source reference
- 0173-0893_dd604365-bcae-4ef7-a69e-71dcbebfa98b
- Product NDC
- 0173-0893
- Form
- POWDER
- Composition / generic term
- fluticasone furoate, umeclidinium bromide and vilanterol trifenatate
- Labeler
- GlaxoSmithKline LLC
- Marketing category
- NDA
- Marketing start / end (source format)
- 20200909
- Source listing expiry
- 20271231
Source-listed ingredients
- FLUTICASONE FUROATE — 200 ug/1
- UMECLIDINIUM BROMIDE — 62.5 ug/1
- VILANTEROL TRIFENATATE — 25 ug/1
These values do not establish equivalence or a dose recommendation.
Packages
- 1 TRAY in 1 CARTON (0173-0893-10) / 1 INHALER in 1 TRAY / 30 POWDER in 1 INHALER · 0173-0893-10
- 1 TRAY in 1 CARTON (0173-0893-14) / 1 INHALER in 1 TRAY / 14 POWDER in 1 INHALER · 0173-0893-14
- 1 TRAY in 1 CARTON (0173-0893-61) / 1 INHALER in 1 TRAY / 14 POWDER in 1 INHALER · 0173-0893-61
Source and coverage
Open FDA National Drug Code directory →
Snapshot retrieved: 2026-09-17. This is the acquisition date, not a medical review date.
Clinical information, images and comparisons appear only when separately reviewed for this record. Coverage may be incomplete. Ask a pharmacist or clinician about your treatment.
Browse United States records →